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Nicolas Roche6, Nina Skavlan Godtfredsen7, Thys van der Molen8, Claes-Göran Löfdahl9, Laura Padullés10
and Anna Ribera10Abstract
Background: Few studies have investigated the 24-hour symptom profile in patients with COPD or how symptoms
during the 24-hour day are inter-related. This observational study assessed the prevalence, severity and relationship
between night-time, early morning and daytime COPD symptoms and explored the relationship between 24-hour
symptoms and other patient-reported outcomes.
Methods: The study enrolled patients with stable COPD in clinical practice. Baseline night-time, early morning and
daytime symptoms (symptom questionnaire), severity of airflow obstruction (FEV1), dyspnoea (modified Medical
Research Council Dyspnoea Scale), health status (COPD Assessment Test), anxiety and depression levels (Hospital
Anxiety and Depression Scale), sleep quality (COPD and Asthma Sleep Impact Scale) and physical activity level
(sedentary, moderately active or active) were recorded.
Results: The full analysis set included 727 patients: 65.8% male, mean ± standard deviation age 67.2 ± 8.8 years,
% predicted FEV1 52.8 ± 20.5%.
In each part of the 24-hour day, >60% of patients reported experiencing ≥1 symptom in the week before baseline.
Symptoms were more common in the early morning and daytime versus night-time (81.4%, 82.7% and 63.0%,
respectively). Symptom severity was comparable for each period assessed. Overall, in the week before baseline, 56.7% of
patients had symptoms throughout the whole 24-hour day (3 parts of the day); 79.9% had symptoms in ≥2 parts of the
24-hour day. Symptoms during each part of the day were inter-related, irrespective of disease severity (all p < 0.001).
Early morning and daytime symptoms were associated with the severity of airflow obstruction (p < 0.05 for both). Night-
time, early morning and daytime symptoms were all associated with worse dyspnoea, health status and sleep quality, and
higher anxiety and depression levels (all p < 0.001 versus patients without symptoms in each corresponding period). In
each part of the 24-hour day, there was also an association between symptoms and a patient’s physical activity level
(p < 0.05 for each period).
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Conclusions: More than half of patients experienced COPD symptoms throughout the whole 24-hour day. There was a
significant relationship between night-time, early morning and daytime symptoms. In each period, symptoms were
associated with worse patient-reported outcomes, suggesting that improving 24-hour symptoms should be an
important consideration in the management of COPD.
Keywords: Anxiety, ASSESS, COPD, Depression, Dyspnoea, Health status, Observational, Relationship, Sleep quality,
SymptomsBackground
Despite being preventable and treatable, chronic ob-
structive pulmonary disease (COPD) is associated with
considerable morbidity and mortality [1,2] and its preva-
lence is expected to increase in the coming decades [3].
The characteristic symptoms of COPD include breath-
lessness, cough and increased sputum production and,
based on cohort studies, there is now extensive evidence
that COPD symptoms have a considerable impact on
patients’ daily activities, health status and quality of life
[4-8]. Furthermore, while COPD is diagnosed clinically
based on persistent airflow limitation, it is the impact of
symptoms on patients’ daily lives that generally drives
them to seek a diagnosis. The importance of considering
COPD symptoms in the overall assessment of COPD,
and in determining appropriate treatment approaches, is
now recognised [9]. Reducing symptoms, improving
health status and increasing physical activity are major
goals in the management of stable COPD [9].
COPD symptoms have been reported to vary through-
out the day [10-12]. In cohort studies, patients with
COPD who were receiving ongoing treatment with their
normal COPD medication reported that their symptoms
were worst in the morning [10,12]. Morning symptoms
impact on patients’ normal activities [8,10,12,13] and
have been demonstrated to be associated with worse
health status and a higher risk of COPD exacerbations
[8,13]. In the working population, morning symptoms
were also significantly associated with increased annual
absenteeism [13]. With regard to night-time symptoms,
a recent real-world study also demonstrated that pa-
tients with night-time symptoms had significantly worse
health status, more sleep disturbances and higher health-
care resource utilisation than patients without night-
time symptoms [7].
In a pan-European, observational study, patients’
perception of the variability of their breathlessness was
associated with both the severity of breathlessness and
frequent exacerbations [10], while the pattern of COPD
symptom variability has been shown to be influenced by
disease severity [12]. Previous studies have also shown
an association between morning or night-time symp-
toms and reduced lung function [7,13,14]. However, theassociation between symptoms in each part of the
24-hour day and the severity of airflow obstruction and
the inter-relationship between 24-hour COPD symptoms
has not previously been investigated in a single patient
cohort.
In this observational study, we investigated the
prevalence and severity of night-time, early morning and
daytime symptoms in patients with stable COPD being
treated in clinical practice and explored the relationship
between symptoms in each part of the 24-hour day.
Additionally, to better understand the relationship be-
tween 24-hour symptoms and other aspects of a patient’s
overall well-being, we assessed their association with the
severity of airflow obstruction and other patient-
reported outcomes, including self-perceived dyspnoea,
health status, anxiety and depression levels, sleep quality
and physical activity level.
Methods
Study design
This was a multinational, non-interventional, observa-
tional study conducted in 85 clinical practice centres
(pulmonologists outpatients and primary care) across
Denmark, France, Germany, Italy, The Netherlands,
Spain, Sweden and UK (see Additional file 1 for a list of
investigators). Patients who met the eligibility criteria
were identified consecutively at each site, with each site
having a maximum quota to minimise selection bias.
The study consisted of a baseline visit (Day 1) and a
follow-up telephone interview after 6 months. There
were no interventions beyond routine clinical care
delivered at the discretion of the physician.
A steering committee, comprising the study country
co-ordinators, was involved in the design of the study.
The protocol was approved by all necessary ethics
committees, as required by law for each country, before
study initiation (see Additional file 2 for a list of approval
authorities for each country). All patients provided written
informed consent.
Study population
Patients were aged ≥40 years with mild to very severe
COPD according to the Global Initiative for Chronic
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tion [15], (spirometry data from the year before baseline
were considered valid). Patients were current or former
smokers with a smoking history of ≥10 pack-years and
had no history of COPD exacerbation in the previous
month.
Exclusion criteria were: any change in maintenance
COPD treatment in the previous 3 months; a previous
diagnosis of asthma, sleep apnoea syndrome or chronic
respiratory disease other than COPD; and any acute or
chronic condition that would limit the patient’s ability to
complete the questionnaires.
Assessments
Night-time, early morning and daytime symptoms,
severity of airflow obstruction, dyspnoea severity, health
status, anxiety and depression levels, sleep quality and
physical activity levels were assessed at baseline. COPD
symptoms were assessed using a Night-time, Morning
and Daytime Symptoms of COPD questionnaire devel-
oped by the study sponsor. To ensure accurate transla-
tion and a clear understanding of the questionnaire in
each participating country, linguistic validation based on
five patients per country was performed before use of
the questionnaire in the study. The Night-time, Morning
and Daytime Symptoms of COPD questionnaire is a 33-item
questionnaire that asks the patient about the preva-
lence, frequency and severity of COPD symptoms during
each part of the day during (i) the week before baseline and
(ii) a typical week in the month before baseline (defined
as a week the patient considers most usual for them in
the previous month). In addition, the questionnaire also
contained questions related to sleep disturbances, rescue
medication, anxiety due to symptoms, limitation of
activities due to symptoms and concentration levels. The
questionnaire consists of three parts (one part for each
period during the 24-hours) and includes 13 items for
night-time symptoms, ten items for morning symptoms
and ten items for daytime symptoms. Night-time corre-
sponds to the time from when the patient goes to bed
until they get out of bed to start the day; morning is the
time from getting out of bed until approximately 11 am;
and daytime is from approximately 11 am until the patient
goes to bed. Patients were asked about the frequency of
symptoms related to breathlessness, coughing, bringing
up phlegm or mucus, chest tightness, chest congestion
and wheezing during each period. Patients were also
asked about the overall severity of their night-time, early
morning and daytime symptoms during the last week;
symptom severity was scored as 1 (no symptoms); 2 (mild);
3 (moderate); 4 (severe) or 5 (very severe).
Dyspnoea was assessed using the modified Medical
Research Council (mMRC) scale [16] with patients
assessing their perceived breathlessness on a scale of 0(breathlessness with strenuous exercise) to 4 (too breath-
less to leave the house or breathless when dressing or
undressing). Health status was assessed using the COPD
Assessment Test (CAT; total score range 0–40, <10 indi-
cates low impact, 10–20 medium impact, 21–30 high
impact, >30 very high impact on health status) [17]. Self-
perceived anxiety and depression levels were assessed
using the Hospital Anxiety and Depression Scale [18-21]
(HADS; total score range 0–21 where ≥8 indicates a prob-
able diagnosis [22,23]). Sleep quality was assessed using
the COPD and Asthma Sleep Impact Scale (CASIS)
[24,25]. Patients assessed the frequency of a range of sleep
problems on a scale of 1 (never) to 5 (very often; several
items are reverse-scored); individual item scores were
summed to give a total raw score, which was linearly
transformed to total scale score (range 1–100); higher
scores indicate greater sleep impairment. At baseline,
patients were also assessed as being sedentary (does not
perform any type of physical activity), moderately active
(patient performs some type of exercise two or three times
a week) and active (patient plays sports or exercises more
than three times a week).
Study outcomes
Primary endpoints in the study were the prevalence, se-
verity, and inter-relationships for night-time, early morn-
ing and daytime symptoms at baseline (assessed based
on the Night-time, Morning and Daytime Symptoms of
COPD questionnaire). To further explore the relation-
ship between 24-hour symptoms and other aspects
of COPD that affect patients’ well-being, secondary
endpoints included the relationship between night-time,
early morning and daytime symptoms and severity of
COPD, dyspnoea severity, health status, levels of anxiety
and depression, sleep quality and physical activity levels.
Statistical analyses
All analyses were performed using the full analysis set,
which comprised all patients who fulfilled the eligibility
criteria and who completed the Night-time, Morning
and Daytime Symptoms of COPD questionnaire. The
data were analysed using only the available data for each
outcome. Descriptive data are reported as mean ± stand-
ard deviation (SD) or percentages, as appropriate. The
relationship between symptoms in each part of the day
and baseline characteristics or patient-reported out-
comes was assessed using univariate analysis. The rela-
tionship between symptoms in each part of the day,
symptoms and airflow limitation, symptoms and comor-
bidities and symptoms and physical activity level was
assessed using a chi-squared test. The relationship be-
tween night-time, early morning or daytime symptoms
and dyspnoea, health status, anxiety and depression
levels, and sleep quality was assessed using a Wilcoxon
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a 5% significance level; there was no adjustment for multi-
plicity. All statistical analyses were performed using SAS
(version 9.1.3 or later; SAS Institute Inc., Cary, NC, USA).
A sample size of 680 patients offered a maximum mar-
gin of error (minimum precision) of 4% for estimating
the percentage of patients with night-time, early morn-
ing and daytime symptoms, considering maximum inde-
termination (p = 50%) and a confidence level of 95%.
Anticipating that approximately 5% of patients would
have missing data or a major protocol violation, the final
sample size was set at 720 patients.Results
Patients
Of 743 patients who enrolled in the study and had a
baseline visit, 727 were eligible for inclusion in the full
analysis set. Demographics and baseline characteristics
are shown in Table 1; 72.4% of patients had a diagnosis
of moderate or severe COPD (based on severity of
airflow limitation) and 58.9% had dyspnoea assessed on
the mMRC scale as grade ≥2. Overall, 50.9% of patients
were receiving treatment with triple therapy (long-acting
β2-agonists [LABA], long-acting muscarinic antagonists
[LAMA] plus inhaled corticosteroids), with or without a
phosphodiesterase 4 (PDE4) inhibitor (2.1% and 48.8%,
respectively). In addition to COPD, 79.4% of patients
had a comorbid medical condition; 45.1% of patients
had a diagnosis of hypertension and 33.7% had cardio-
vascular disease. Based on physical activity level, 30.0%
of patients were assessed as being sedentary, 38.1% as
moderately active and 31.4% as active at baseline.Prevalence and severity of COPD symptoms in each part
of the 24-hour day
The prevalence of COPD symptoms in each part of the
24-hour day is shown in Figure 1. In each part of the
24-hour day, >60% of patients experienced at least one
COPD symptom in the week before baseline (Figure 1).
Early morning and daytime symptoms were most com-
mon, however 63.0% of patients experienced at least one
night-time symptom in the week before baseline and
more than half of the patients (52.0%) reported having
night-time symptoms at least three times during a
typical week.
Patients’ assessment of the severity of their night-time,
early morning and daytime symptoms is shown in
Table 2. In symptomatic patients the overall severity of
symptoms was comparable for the night-time, early
morning and daytime periods (Table 2). In each part of
the 24-hour day, most people assessed their symptoms
during the previous week as mild or moderate (night-
time 89.5%, early morning 87.9% and daytime 89.3%).Individual COPD symptoms
When individual symptoms were assessed, symptoms
related to breathlessness were most common (71.4% of pa-
tients) followed by coughing (65.9%), bringing up phlegm
or mucus (59.6%), wheezing (41.4%), chest tightness
(32.9%) and chest congestion (23.4%). The frequency and
pattern of each individual symptom varied throughout the
24-hour day (Figure 2). The proportion of patients report-
ing breathlessness increased from night-time through the
morning and into the daytime, whereas coughing and
bringing up phlegm or mucus were most common early in
the morning. Coughing and bringing up phlegm or mucus
were the most common symptoms reported during the
night-time.
Relationship between COPD symptoms in each part of
the 24-hour day
In the week before baseline, 90.5% of patients experi-
enced COPD symptoms during at least one part of the
24-hour day (Figure 3). More than half of patients
(56.7%) experienced symptoms throughout the whole
24-hour day; 10.6% of patients had symptoms in only
one part (Figure 3). Almost 60% of patients had both
night-time and early morning symptoms (Table 3).
Among patients with night-time symptoms, 94.3% also
had early morning symptoms while 73.3% of those with
early morning symptoms also had night-time symptoms.
A similar pattern was observed for the combinations of
night-time and daytime symptoms (Table 3).
When the relationships between symptoms during
each part of the 24-hour day were assessed, there was a
significant association for each potential symptom com-
bination (night-time and early morning symptoms;
night-time and daytime symptoms; and early morning
and daytime symptoms; all p < 0.001). The relationships
between night-time, early morning and daytime symp-
toms were maintained for all symptom combinations,
irrespective of the severity of airflow limitation (mild to
very severe all p < 0.05).
Relationship between COPD symptoms in each part of
the 24-hour day and other aspects of COPD
The overall proportion of patients with any COPD symp-
tom and the prevalence of night-time, early morning and
daytime symptoms, according to COPD severity (based
on airflow limitation) are shown in Figure 4A and B.
Irrespective of the severity of airflow obstruction, >80% of
patients in each severity category experienced COPD
symptoms (Figure 4A). Overall, there was a significant re-
lationship between COPD severity and symptoms during
the early morning and the daytime (both p < 0.05). How-
ever, the relationship between night-time symptoms and
COPD severity did not reach statistical significance and
the proportion of patients with night-time symptoms was
Table 1 Demographics and baseline characteristics
Characteristic Eligible patients
(N = 727)
Sex, n (%), male 478 (65.8)
Age, mean (SD), years (n = 725) 67.2 (8.8)
BMI, mean (SD), kg/m2 (n = 720) 26.4 (5.2)
Current smoker, n (%) 202 (27.8)
Smoking history, mean (SD), pack-years (n = 723) 43.1 (24.8)
Post-bronchodilator FEV1, mean (SD), L (n = 696) 1.4 (0.6)
% predicted FEV1, mean (SD) (n = 718) 52.8 (20.5)
COPD severity, n (%)
GOLD group I (mild) 63 (8.7)
GOLD group II (moderate) 265 (36.5)
GOLD group III (severe) 261 (35.9)
GOLD group IV (very severe) 73 (10.0)
mMRC grade, mean (SD) 1.8 (1.0)






Patients with an exacerbation in previous year, n (%) 392 (53.9)
Number of COPD exacerbations in previous year,
mean (SD) (n = 724)
1.2 (1.6)
Current COPD medication, n (%)a
LABAs + LAMAs + ICS 355 (48.8)
LABAs + ICS 100 (13.8)
LABAs + LAMAs 70 (9.6)
LABAs alone 66 (9.1)
LAMAs alone 50 (6.9)
Short-acting bronchodilatorsb 22 (3.0)
LABAs + LAMAs + ICS + PDE4 inhibitor 15 (2.1)
LAMAs + ICS 8 (1.1)
Otherc 19 (2.6)
No treatment 22 (3.0)
Total CAT score, mean (SD) (n = 721) 16.5 (8.1)
CAT score category, n (%)
CAT score ≤10, n (%) 187 (25.7)
CAT score 11–20, n (%) 305 (42.0)
CAT score 21–30, n (%) 187 (25.7)
CAT score >30, n (%) 42 (5.8)
Table 1 Demographics and baseline characteristics
(Continued)
HADS anxiety score, mean (SD) (n = 710) 6.1 (4.2)
HADS depression score, mean (SD) (n = 714) 5.5 (4.1)
CASIS score, mean (SD) (n = 712) 44.1 (19.1)
n = patients with available data for each outcome; percentages are based on
N = 727 patients.
aUsed by >1% of patients.
bIncludes: SABA alone; SABA + SAMA; SAMA alone.
cIncludes: ICS alone; ICS + PDE4 inhibitor; LABA + ICS + PDE4 inhibitor;
LAMA + LABA + PDE4 inhibitor.
BMI, body mass index; CASIS, COPD and Asthma Sleep Impact Scale; CAT, COPD
Assessment Test; COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung
Disease; HADS, Hospital Anxiety and Depression Scale; ICS, inhaled corticosteroid;
LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; mMRC,
modified Medical Research Council; PDE4, phosphodiesterase 4; SABA, short-acting
β2 agonist; SAMA, short-acting muscarinic antagonist; SD, standard deviation.
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estingly, there was also no significant relationship between
COPD severity and the number of parts of the 24-hour
day when patients experienced symptoms (p = 0.125);
47.6% of patients with mild COPD reported symptoms
during the whole 24-hour day during the week before
baseline compared with 63.0% of patients with very severe
COPD.
There was a significant relationship between night-
time, early morning and daytime symptoms and the
severity of self-perceived dyspnoea (all p < 0.001; Table 4).
Mean mMRC grades were significantly higher in patients
with symptoms compared with patients without symp-
toms in each corresponding part of the 24-hour day
(Table 4). There was also an association between the
number of parts of the 24-hour day when patients expe-
rienced symptoms and dyspnoea severity (p < 0.001).
Most patients who had grade ≥2 dyspnoea assessed on
the mMRC dyspnoea scale had symptoms throughout
the whole 24-hour day (63.8%); this compares with
46.5% of patients assessed as mMRC grade <2. There
was no significant relationship between night-time, early
morning or daytime symptoms and the presence of
comorbidities in these patients.
In each part of the 24-hour day, including night-time,
there was a significant relationship between symptoms
and health status, anxiety and depression levels, and
sleep quality (all p < 0.001 versus no symptoms; Table 4).
In each period, mean CAT scores were >7.5 points
higher in patients with symptoms versus patients with-
out symptoms (Table 4). Based on HADS score at base-
line, 34.5% of patients had anxiety and 27.6% had
depression. When assessed according to patients with
and without symptoms in each part of the 24-hour day,
mean HADS anxiety and depression scores were signifi-
cantly higher in patients with symptoms versus those
without symptoms (p < 0.001 for all; Table 4). Sensitivity
analyses performed in patients with no medical history
Figure 1 Prevalence and frequency of night-time, early morning and daytime COPD symptoms (N = 727). aA typical week refers to a week
that the patient considered most usual for them during the previous month. COPD, chronic obstructive pulmonary disease.
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a significant association between symptoms and HADS
anxiety and depression scores in each part of the
24-hour day (all p < 0.001). Patients with symptoms also
had significantly higher CASIS scores compared with
those without symptoms (p < 0.001 for all; Table 4),
indicating greater sleep impairment. When patients who
were receiving sleep medications or treatment for benign
prostatic hyperplasia (n = 109) were excluded from the
analyses of CASIS scores, the relationship between
night-time, early morning and daytime symptoms and
sleep quality remained significant in each period (data
not shown).
In each part of the 24-hour day, there was a significant
relationship between symptoms and patients’ physical
activity level at baseline (assessed as sedentary, moder-
ately active or active; p < 0.05 for each part of the 24-hour
day). There was also a significant relationship for the
number of parts of the 24-hour day when patientsTable 2 Patients’ assessment of night-time, early morning




No. of patients (%)
Night-time Early morning Daytime
(n = 409a) (n = 571a) (n = 589a)
Mild 191 (46.7) 252 (44.1) 254 (43.1)
Moderate 175 (42.8) 250 (43.8) 272 (46.2)
Severe 39 (9.5) 61 (10.7) 59 (10.0)
Very severe 4 (1.0) 8 (1.4) 4 (0.7)
aPatients who reported symptoms during the previous week and provided
data for symptom severity.
COPD, chronic obstructive pulmonary disease.experienced symptoms and physical activity levels
(p = 0.006). A higher proportion of patients who were
sedentary had symptoms throughout the whole 24-hour
day compared with patients who were active (64.2% versus
50.4%, respectively).
Mean CAT, HADS anxiety and depression, and CASIS
scores according to each 24-hour symptom combination
are shown in Figure 5. Patients with symptoms through-
out the whole 24-hour day had the worst health status
and sleep quality and the highest levels of anxiety and
depression. CAT scores were higher in patients with
symptoms during two or more parts of the 24-hour day
than in patients with only night-time, early morning or
daytime symptoms (Figure 5A). With the exception of
patients with early morning and daytime symptoms,
patients who reported night-time symptoms, either
alone or in combination, had the highest anxiety levels
(Figure 5B) and patients with any combination of early
morning and night-time symptoms had the highest
depression levels (Figure 5C). A similar pattern was
generally observed when HADS scores were analysed in
patients with no medical history of anxiety or depres-
sion (Additional file 3). Patients with any night-time
symptoms had worse sleep quality than patients with-
out night-time symptoms (Figure 5D).
Discussion
In this observational study, more than half of patients
reported experiencing COPD symptoms throughout the
whole 24-hour day, despite receiving ongoing treatment
for their COPD and almost 80% of patients had symptoms
during at least two parts of the 24-hour day. While early
morning and daytime symptoms were most frequent,
Figure 2 Prevalence of individual COPD symptoms throughout the 24-hour day in the week before baseline (N = 727). COPD, chronic
obstructive pulmonary disease.
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two-thirds of patients experienced at least one night-time
symptom during the week before baseline. Importantly,
any symptoms in the early morning, daytime or night-
time were associated with worse outcomes across a range
of patient-reported measures including more severe dys-
pnoea, higher anxiety and depression levels and worse
health status and sleep quality.Figure 3 Prevalence of COPD symptoms during one, two or three par
COPD, chronic obstructive pulmonary disease.The observation that a large majority of patients
experienced symptoms during at least two parts of the
24-hour day is consistent with results from a recent
real-world study in almost 1500 patients. The study by
Roche et al. showed that most patients had symptoms
during the daytime and night-time and only 34% of pa-
tients experienced COPD symptoms in isolation during
one part of the 24-hour day [13]. However, in contrastts of the 24-hour day in the week before baseline (N = 727).
Table 3 Proportion estimates of night-time, early morning and daytime COPD symptom combinations
Symptom combinations % (n/N) [95% CI]
Night-time (NT) and early morning (EM) symptoms
Overall patients with both NT and EM symptoms 59.8 (432/723) 56.1, 63.3
Patients with ≥1 NT symptom (n = 458) who also had ≥1 EM symptom 94.3 (432/458) 91.8, 96.1
Patients with ≥1 EM symptom (n = 589) who also had ≥1 NT symptom 73.3 (432/589) 69.6, 76.8
Night-time (NT) and daytime (DT) symptoms
Overall patients with both DT and NT symptoms 59.4 (429/722) 55.8, 62.9
Patients with ≥1 NT symptom (n = 458) who also had ≥1 DT symptom 93.7 (429/458) 91.1, 95.6
Patients with ≥1 DT symptom (n = 598) who also had ≥1 NT symptom 71.7 (429/598) 68.0, 75.2
Early morning (EM) and daytime (DT) symptoms
Overall patients with both EM and DT symptoms 75.0 (544/725) 71.7, 78.1
Patients with ≥1 EM symptom (n = 591) who also had ≥1 DT symptom 92.1 (544/591) 89.6, 94.0
Patients with ≥1 DT symptom (n = 601) who also had ≥1 EM symptom 90.5 (544/601) 87.9, 92.6
n = patients with available data for each combination.
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symptoms were by far the most prevalent (97% of patients)
with just over one-third of patients reporting symptoms
when getting up in the morning. This discrepancy may
relate to the different definitions of morning symptoms
used; the Roche et al. study defined morning symptoms as
those present on waking and did not include those
symptoms that persisted later in the morning [13].
There is no objective definition of ‘night-time symp-
toms’ in patients with COPD, and it has been suggested
that night-time symptoms may be under-reported by
physicians or may not be reported by patients [26]. The
results of our study are consistent with a previous study
in 2807 patients, which demonstrated that approxi-
mately 70% of patients reported experiencing night-time
symptoms [7]. Together these data suggest a high preva-
lence of night-time symptoms in patients with COPD.
Lung function exhibits circadian variation with reduced
airflow during the night-time period [27]. The amplitude
of this circadian variation has been shown to be in-
creased in patients with COPD [28,29] and it may
contribute to night-time symptoms [26,28]. In a previous
study, wheezing was the most troublesome symptom at
night, followed by cough [10]. In the present study
cough and bringing up phlegm were the most prevalent
night-time symptoms suggesting that, in addition to
reduced airflow, other mechanisms may be involved in
mediating night-time symptoms including mucus hyper-
secretion, reduced ciliary activity or increased cough
sensitivity. Further investigation of these processes is re-
quired to better understand the pathophysiology under-
lying night-time COPD symptoms.
Early morning symptoms have been reported to be
most problematic for patients with COPD and can sig-
nificantly impact on daily activities [10-12] and working
life [13]. Furthermore, in a previous study, a quarter ofpatients with COPD reported that night-time symptoms
were most troublesome and night-time was the second
most problematic time for patients with severe COPD
[12]. However, despite patients frequently reporting
night-time symptoms, the impact that symptoms at
night has on daily activities, such as getting up for
work, is often under-estimated by physicians [7]. Previous
studies have shown a significant association between
night-time symptoms and the severity of airflow obstruc-
tion in patients with COPD [7,14]. Interestingly, our re-
sults show that whilst there was a significant relationship
between early morning and daytime symptoms and the se-
verity of airflow limitation, this association was not signifi-
cant for night-time symptoms and the prevalence of
night-time symptoms was comparable across all severities
of airflow limitation. Furthermore, symptoms in each part
of the 24-hour day were inter-related, an observation that
was consistent irrespective of COPD severity. These data
suggest that the presence of night-time symptoms is not
merely a consequence of more severe airflow limitation.
Other mechanisms, such as decreased mucociliary
clearance, could be involved. However, this study did not
differentiate between different phenotypes of patients with
COPD and further studies are required to determine if
night-time symptoms are associated with a specific
phenotype.
In each part of the 24-hour day, symptoms were asso-
ciated with worse dyspnoea, health status, higher anxiety
and depression levels, and greater sleep impairment.
These are all outcomes that can impact on patients’ daily
living and overall well-being. The difference in CAT
scores between patients with and without symptoms in
each period exceeded the estimated minimal clinically
important difference (2 points) recently proposed [30],
suggesting that symptoms in any part of the 24-hour day
may be associated with a clinically meaningful worsening
Figure 4 Prevalence of any COPD symptoms (A) overall and (B) during each part of the 24-hour day, according to COPD severity.
n = patients in each group based on available data. COPD, chronic obstructive pulmonary disease.
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http://respiratory-research.com/content/15/1/122of health status. Moreover, anxiety and depression levels
were also significantly higher in patients with symptoms
compared with patients without symptoms. In general,
anxiety levels tended to be highest in patients who had
any combination of night-time symptoms and depression
levels were highest in patients with any combination ofnight-time/early morning symptoms. Depression is a
common comorbidity in patients with COPD [2] and
patients with severe COPD have a 2.5-fold higher risk
of depression compared with matched controls [31].
Comorbid depression is associated with an increased
risk of exacerbation and mortality in patients with
Table 4 Patient-reported outcomes in patients with/without COPD symptoms during each part of the 24-hour day
Night-time symptoms Early morning symptoms Daytime symptoms
Patient-reported
outcome
No symptoms ≥1 symptom p-value No symptoms ≥1 symptom p-value No symptoms ≥1 symptom p-value
mMRC grade, 1.6 1.9 <0.001 1.4 1.9 <0.001 1.4 1.9 <0.001
mean (95% CI) (1.5, 1.7) (1.8, 2.0) (1.2, 1.5) (1.8, 2.0) (1.2, 1.6) (1.8, 2.0)
(n = 265) (n = 457) (n = 134) (n = 591) (n = 124) (n = 600)
CAT score, 11.6 19.3 <0.001 9.8 18.1 <0.001 10.0 17.9 <0.001
mean (95% CI) (10.8, 12.4) (18.6, 20.0) (8.8, 10.9) (17.4, 18.7) (8.9, 11.1) (17.3, 18.5)
(n = 263) (n = 455) (n = 133) (n = 588) (n = 124) (n = 596)
HADS anxiety score, 4.6 6.9 <0.001 4.1 6.5 <0.001 4.2 6.5 <0.001
mean (95% CI) (4.1, 5.1) (6.5, 7.3) (3.4, 4.7) (6.2, 6.9) (3.5, 4.8) (6.1, 6.8)
(n = 262) (n = 445) (n = 133) (n = 577) (n = 123) (n = 586)
HADS depression score, 4.2 6.2 <0.001 3.4 6.0 <0.001 3.7 5.9 <0.001
mean (95% CI) (3.8, 4.6) (5.8, 6.6) (2.9, 4.0) (5.6, 6.3) (3.1, 4.4) (5.5, 6.2)
(n = 263) (n = 448) (n = 132) (n = 582) (n = 123) (n = 590)
CASIS score, 33.6 50.2 <0.001 34.4 46.3 <0.001 34.2 46.2 <0.001
mean (95% CI) (31.9, 35.2) (48.4, 52.0) (31.7, 37.1) (44.8, 47.9) (31.4, 37.0) (44.7, 47.8)
(n = 260) (n = 449) (n = 131) (n = 581) (n = 122) (n = 589)
P values determined using Wilcoxon rank-sum test versus no symptoms in each period.
n = patients with available data for each outcome.
CASIS, COPD and Asthma Sleep Impact Scale; CAT, COPD Assessment Test; CI, confidence interval; COPD, chronic obstructive pulmonary disease; HADS, Hospital
Anxiety and Depression Scale; mMRC, modified Medical Research Council.
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http://respiratory-research.com/content/15/1/122COPD [32]. Since symptoms of depression tend to be
worse in the morning we cannot rule out that higher
levels of depression contribute to night-time and morn-
ing COPD symptoms. Of note, examining questions on
COPD symptoms and the HADS questionnaire does
not reveal common items, making confounding by
wording unlikely. Finally, a similar pattern in the
magnitude of HADS scores and symptom combinations
was observed in patients with no medical history of
anxiety or depression. Sleep was also significantly im-
paired in patients with symptoms in any part of the
24-hour day compared with patients without symptoms.
As expected, the greatest impairment was observed in
patients with night-time symptoms. Poor sleep quality or
sleep disturbance in patients with COPD has been shown
to be associated with worse health status, more exacerba-
tions, increased healthcare resource utilisation and in-
creased mortality [7,33]. In this study, we also observed a
significant relationship between symptoms in any part of
the 24-hour day and physical activity levels: patients who
were sedentary had more symptoms in each period than
patients who were even moderately active. This may be
important as low physical activity levels are significantly
associated with poor quality of life and increased incidence
of depression in patients with COPD [34] and have been
shown to be a strong predictor of mortality in patients
with COPD [35,36], and improving physical activity is an
important goal in the treatment of COPD [9].Overall, our results support previous studies showing
that symptoms during the morning and the night-time
are independently associated with worse outcomes in pa-
tients with COPD [7,13]. COPD symptoms when getting
up in the morning have been shown to be independently
associated with worse health status and more exacerba-
tions, and have a negative impact on daily activities [13].
Similarly, patients with night-time symptoms had signifi-
cantly worse breathlessness and health status and were
more likely to have morning symptoms than patients
without night-time symptoms, even when these analyses
were controlled for confounding factors such as disease
severity [7]. Our results extend these studies by demon-
strating that there is an inter-relationship between symp-
toms in each part of the 24-hour day and that symptoms
in any part of the day are associated with worse patient-
reported outcomes.
While these results demonstrate significant relation-
ships between symptoms in each part of the 24-hour day
and various aspects of patients’ well-being, the analyses
do not take into account confounding factors such as
disease severity or comorbid conditions, which may also
impact on patient-reported outcomes. Furthermore, no
causal relationship can be inferred from the analyses as
this was an observational study. Further investigation of
the specific relationship between symptoms in each part
of the 24-hour day and each outcome is required to
establish whether symptoms are independently associated
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Figure 5 (A) Health status, (B) anxiety, (C) depression and (D)
sleep quality according to each combination of 24-hour COPD
symptoms. n = patients with available data for each outcome. CASIS,
COPD and Asthma Sleep Impact Scale; CAT, COPD Assessment Test;
COPD, chronic obstructive pulmonary disease; HADS, Hospital Anxiety
and Depression Scale; SD, standard deviation.
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http://respiratory-research.com/content/15/1/122with the outcome, irrespective of underlying disease. While
this study enrolled patients with mild to very severe COPD,
only patients being treated in clinical practice (both pri-
mary care and specialist centres) were assessed. As such,
the relevance of these observations for the wider popula-
tion of patients with COPD, including those with undiag-
nosed COPD, requires further consideration.
Conclusions
The results of this study demonstrate that despite receiv-
ing treatment for COPD, more than half of patients con-
tinued to have symptoms throughout the whole 24-hour
day, including during the night-time and early morning
periods. The relationship between night-time, early
morning and daytime symptoms was observed irrespect-
ive of the severity of airflow obstruction. Patients with
symptoms during any part of the 24-hour day also had
significantly worse outcomes across a range of measures
that impact on daily living, including health status,
anxiety and depression levels and sleep quality compared
with patients without symptoms. This suggests that
current approaches to managing COPD may not ad-
equately control symptoms, which can impact on a
patient’s overall well-being. Newer therapies, including
long-acting bronchodilators that are administered twice-
daily or ultra-long-acting bronchodilators, may be useful
in improving symptom control during the night-time,
whereas those with a rapid onset of action may have
advantages in controlling early morning symptoms. It is
important for physicians to manage patients’ symptoms
throughout the 24-hour day, even in those with mild
airflow obstruction.
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